Lesnik P, Vonica A, Guérin M, Moreau M, Chapman M J
Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Arterioscler Thromb. 1993 Jul;13(7):1066-75. doi: 10.1161/01.atv.13.7.1066.
Human plasma contains a multivalent, Kunitz-type proteinase inhibitor termed tissue factor pathway inhibitor (TFPI), which specifically inhibits the action of the factor VII(a)-tissue factor complex in coagulation. In the present study, we examined the distribution and anticoagulant activity of TFPI among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; this procedure permitted the simultaneous fractionation of the major lipoprotein classes (very-low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], low-density lipoprotein [LDL], high-density lipoprotein [HDL] 2 and 3, and very-high-density lipoprotein [VHDL]). Studies of eight normolipidemic subjects revealed two major lipoprotein carriers of TFPI activity: dense LDL subspecies (d = 1.039 to 1.063 g/mL) and both dense HDL particles and VHDL (d = 1.133 to 1.190 g/mL), representing 33.8% and 35.9%, respectively, of the total lipoprotein-associated TFPI activity in plasma. TFPI activity was also associated with lipoprotein(a) (Lp[a]), whose density distribution (d = 1.044 to 1.100 g/mL) overlapped that of LDL and HDL2; such association was related to Lp(a)'s particle size and phenotype. VLDL, IDL, and LDL1 through LDL3 (d = 1.019 to 1.039 g/mL), HDL2 (d = 1.063 to 1.100 g/mL), and light subfractions of HDL3 (d = 1.100 to 1.167 g/mL) conveyed only 1.8%, 10%, and 18.5%, respectively, of lipoprotein-associated TFPI activity. Such anticoagulant activity was dependent on the presence of TFPI protein. The dense subspecies of HDL3 (d = 1.133 to 1.167 g/mL) with which TFPI was preferentially associated were small, displayed a cholesteryl ester to protein ratio of approximately 0.2, and were deficient in phospholipid (13.6% to 18.3%). HDL subspecies of d = 1.110 to 1.167 g/mL mainly contained the higher relative molecular mass form of TFPI of 41 kD (a form that is known to be covalently associated with apolipoprotein [apo] A-II) and minor bands of the 35- and 52-kD forms. The second major localization of TFPI was within the hydrated density range of small, dense LDL particles (d = 1.033 to 1.063 g/mL), which in comparison with light LDL (d = 1.019 to 1.033 g/mL) exhibited a markedly lower proportion of triglyceride and enrichment in cholesteryl ester.(ABSTRACT TRUNCATED AT 400 WORDS)
人血浆中含有一种多价的、库尼茨型蛋白酶抑制剂,称为组织因子途径抑制剂(TFPI),它能特异性抑制凝血过程中因子VII(a)-组织因子复合物的作用。在本研究中,我们检测了通过等密度梯度超速离心分离的血浆脂蛋白亚类中TFPI的分布和抗凝活性;该方法可同时分离主要的脂蛋白类别(极低密度脂蛋白[VLDL]、中间密度脂蛋白[IDL]、低密度脂蛋白[LDL]、高密度脂蛋白[HDL]2和3以及极高密度脂蛋白[VHDL])。对8名血脂正常受试者的研究显示,TFPI活性有两种主要的脂蛋白载体:致密LDL亚类(密度d = 1.039至1.063 g/mL)以及致密HDL颗粒和VHDL(密度d = 1.133至1.190 g/mL),分别占血浆中与脂蛋白相关的TFPI活性总量的33.8%和35.9%。TFPI活性也与脂蛋白(a) [Lp(a)]相关,其密度分布(密度d = 1.044至1.100 g/mL)与LDL和HDL2重叠;这种关联与Lp(a)的颗粒大小和表型有关。VLDL、IDL以及LDL1至LDL3(密度d = 1.019至1.039 g/mL)、HDL2(密度d = 1.063至1.100 g/mL)和HDL3的轻亚组分(密度d = 1.100至1.167 g/mL)分别仅携带1.8%、10%和18.5%的与脂蛋白相关的TFPI活性。这种抗凝活性依赖于TFPI蛋白的存在。与TFPI优先相关的HDL3致密亚类(密度d = 1.133至1.167 g/mL)体积小,胆固醇酯与蛋白质的比例约为0.2,且磷脂含量不足(13.6%至18.3%)。密度d = 1.110至1.167 g/mL的HDL亚类主要含有相对分子质量较高的41 kD形式的TFPI(已知该形式与载脂蛋白[apo] A-II共价结合)以及35 kD和52 kD形式的少量条带。TFPI的第二个主要定位在小而致密的LDL颗粒的水合密度范围内(密度d = 1.033至1.063 g/mL),与轻LDL(密度d = 1.019至1.033 g/mL)相比,其甘油三酯比例明显较低,胆固醇酯含量丰富。(摘要截短至400字)